Myeloproliferative Disorders Clinical Trials
69 clinical trials for Myeloproliferative Disorders across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Pathogenesis of Hematologic Malignancies — RECRUITING
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation — RECRUITING · PHASE1
- Feasibility of a Multi-omics Platform for Hematological Malignancies — RECRUITING · NA
- Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) — RECRUITING · NA
- INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) — RECRUITING · NA
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
- Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE) — RECRUITING · NA
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry — RECRUITING
- Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant — RECRUITING · PHASE2
- Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant — RECRUITING · PHASE2
- I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients — RECRUITING · NA
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — ACTIVE_NOT_RECRUITING · PHASE3
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — COMPLETED · PHASE1
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft — ACTIVE_NOT_RECRUITING · PHASE1
- Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 — COMPLETED · NA
- Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation — TERMINATED · PHASE3
- Clonal Hematopoiesis of Immunological Significance — NOT_YET_RECRUITING
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients — ACTIVE_NOT_RECRUITING · PHASE1
- Pegasys® in Patients With Myeloproliferative Diseases — COMPLETED · PHASE2
- Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM) — OTHER
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving — COMPLETED · PHASE1
- Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal — TERMINATED
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow — COMPLETED · PHASE2
- Thrombosomes® in Bleeding Thrombocytopenic Patients Study — TERMINATED · PHASE2
- Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador — COMPLETED
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) — COMPLETED · PHASE3
- In Vitro Drug Sensitivity Testing of Fresh Human Samples — OTHER · NA
- Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT — COMPLETED
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation — WITHDRAWN · PHASE1
- Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis — OTHER
- MSC and HSC Coinfusion in Mismatched Minitransplants — TERMINATED · PHASE2
- Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor — TERMINATED · PHASE2
- Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant — COMPLETED · PHASE2
- Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms — COMPLETED
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF — COMPLETED · PHASE1
- Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry — TERMINATED
- Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT — OTHER · PHASE2
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders — COMPLETED · PHASE2
- PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis — COMPLETED · PHASE1
- Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers — TERMINATED · PHASE2
- Experimental Bone Marrow Transplant Protocol — COMPLETED · PHASE2
- A Study in Myeloproliferative Disorders — COMPLETED · PHASE1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias — TERMINATED · PHASE1
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer — TERMINATED · PHASE1
- Preservation of Ovarian Function After Hematopoietic Cell Transplant — TERMINATED · PHASE2
- Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) — COMPLETED · PHASE4
- T-Reg Cell Kinetics, Stem Cell Transplant, REGALE — TERMINATED · NA
- Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders — WITHDRAWN
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies — COMPLETED · PHASE1
- B-Receptor Signaling in Cardiomyopathy — COMPLETED
Refine this search